Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Authors:
Open Access
- 15 June 2018
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (8) , 1809-1816
Abstract
OBJECTIVE: To assess the effect of empagliflozin on bone fractures and bone mineral density in patients with type 2 diabetes in pooled placebo-controlled trial data and a head-to-head study versus glimepiride. RESEARCH DESIGN AND METHODS: Pooled data were analyzed from patients who were randomized 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in phase I–III clinical trials. Data were also analyzed from the EMPA-REG H2H-SU trial in which patients received empagliflozin 25 mg or glimepiride as an add-on to metformin for 104 weeks with a 104-week extension. Bone fracture adverse events (AEs) were evaluated through a search of investigator-reported (nonadjudicated) events. RESULTS: In the pooled analysis, bone fracture AEs were reported in 119 of 4,221 (2.8%), 105 of 4,196 (2.5%), and 123 of 4,203 (2.9%) patients in the empagliflozin 10 mg, empagliflozin 25 mg, and placebo groups, respectively (rates of 1.55, 1.36, and 1.69/100 patient-years, respectively). In the EMPA-REG H2H-SU trial, bone fracture AEs were reported in 31 of 765 (4.1%) patients receiving empagliflozin 25 mg and in 33 of 780 (4.2%) patients receiving glimepiride (rates of 1.28 and 1.40/100 patient-years, respectively). CONCLUSIONS: Empagliflozin did not increase the risk of bone fracture compared with placebo in a pooled analysis of >12,000 patients or compared with glimepiride in a 4-year head-to-head study.Keywords
Funding Information
- Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance
This publication has 46 references indexed in Scilit:
- A P hase IIb , randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metforminDiabetes, Obesity and Metabolism, 2012
- Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studiesEuropean Journal of Epidemiology, 2012
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism, 2011
- Diabetes and Its Complications and Their Relationship with Risk of Fractures in Type 1 and 2 DiabetesCalcified Tissue International, 2008
- Fracture Risk in Type 2 Diabetes: Update of a Population-Based StudyJournal of Bone and Mineral Research, 2008
- Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of FractureAmerican Journal of Epidemiology, 2007
- Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø studyOsteoporosis International, 2005
- Older Women with Diabetes Have an Increased Risk of Fracture: A Prospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2001